- AU$149.74m
- AU$106.76m
- AU$16.23m
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense
Australia's Orthocell gains most in over a year on US approval for nerve repair device
Brief: Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals
Australia's Orthocell rises after tariff relief on key product
Brief: Orthocell Says US Section 232 Tariffs Not Expected To Affect Remplir
Brief: Orthocell Posts Quarterly Revenue Of A$3.2 Million
Brief: Orthocell Finalises Strategic Investment In Marine Biomedica
Brief: Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 December
Brief: Orthocell Submits Regulatory Application For Commercial Distribution Of Remplir
Australia's Orthocell jumps after nerve repair product sale
Australia's Orthocell jumps on Marine Biomedical stake increase deal
Brief: Orthocell Secures Rights To High-Value Bone Regeneration Tech
Brief: Orthocell Says A$30M Placement Sees Co Positioned For Rapid Growth
Brief: Orthocell Requests Trading Halt For Proposed Capital Raising
Brief: Orthocell Ltd Reports Quarterly Revenue Of A$3.0 Million
Brief: Orthocell Ltd Says Revenue Of A$3.0 Mln Achieved For Quarter Ended 30 Sept